Loading clinical trials...

COMPLETEDPHASE2

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

NCT00478322•Incyte Corporation

Summary

Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Have an established diagnosis of Type 2 Diabetes as determined by the investigator.
•2. Females will be postmenopausal for at least 1 year with documented FSH \> 30 IU/L.

Exclusion Criteria

•1. Hypertriglyceridemia \> 500 mg/dL at screening.
•2. BMI \> 40 kg/m2.
•3. Receiving thiazolidinediones, insulin, or exenatide within the 3 months prior to screening.
•4. History or clinical manifestations of Addison's disease, Cushing's Syndrome, or other disorders involving glucocorticoids or mineralocorticoids.
•5. Current treatment or treatment within 30 days or five half-lives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational protocol.

Locations (3)

Chula Vista, California, United States

The Bronx, New York, United States

San Antonio, Texas, United States

Key Dates

Start Date

April 1, 2007

Primary Completion Date

November 1, 2007

Completion Date

February 1, 2008

Last Updated

December 6, 2016

Enrollment

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2Obesity

Interventions

Placebo

DRUG

INCB013739

DRUG

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 6, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

Protein Supplementation Intervention on Body Weight

Variability In Mixed Meal Tests: Fixed Versus Adjusted to Energy Needs Caloric Dose

iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight Loss